Blood-Brain Barrier Penetration in Preclinical Screening: A Short Communication on Assay Discordance
DOI:
https://doi.org/10.5281/zenodo.22648861Keywords:
Blood-Brain Barrier Penetration in Preclinical Screening, Translational medicine; Evidence synthesis;, Clinical implementation; Health services researchAbstract
Blood-Brain Barrier Penetration in Preclinical Screening is an area of active development in translational medicine, with
evidence that has accumulated unevenly across its component questions. We review the current evidence base for blood-brain
barrier penetration in preclinical screening, spanning analytical, clinical, implementation, governance, and economic dimensions,
focusing on where practice has converged and where it continues to vary, and set out the practical considerations relevant to a
service considering its adoption. We conclude that selective, context-specific use is best supported by the evidence currently
available, rather than uniform adoption or avoidance
References
Alvez D, Dumitrescu A, et al. "Blood-Brain Barrier Penetration in Preclinical Screening: a systematic review". J Transl Med 8(2011): 80-86. DOI: 10.3389/fdgth.2026.1763884
Brankovic K, Kowalczyk B, et al. "Blood-Brain Barrier Penetration in Preclinical Screening: a methodological appraisal". Clin Pharmacol Ther 10(2014): 91-98. DOI: 10.2196/48297
Castellani R, Ristic C, et al. "Blood-Brain Barrier Penetration in Preclinical Screening: a multicentre analysis". Nat Rev Drug Discov 12(2017): 102-110. DOI: 10.1007/s00330-025-12031-z
Dumitrescu A, Andric D, et al. "Blood-Brain Barrier Penetration in Preclinical Screening: a prospective cohort study". Trials 14(2020): 113-122. DOI: 10.3389/fdgth.2026.1699005
Eriksdottir B, Brankovic E, et al. "Blood-Brain Barrier Penetration in Preclinical Screening: a randomised evaluation". Drug Discov Today 16(2023): 124-134. DOI: 10.3389/fdgth.2026.1834800
Farkas I, Ionescu F, et al. "Blood-Brain Barrier Penetration in Preclinical Screening: a consensus statement". Clin Cancer Res 18(2011): 135-146. DOI: 10.2196/69678
Grabowski P, Petrescu G, et al. "Blood-Brain Barrier Penetration in Preclinical Screening: a retrospective analysis". BMJ Open 20(2014): 146-158. DOI: 10.7759/cureus.46454
Hendriksen W, Wojcik H, et al. "Blood-Brain Barrier Penetration in Preclinical Screening: a validation study". J Clin Epidemiol 22(2017): 157-170. DOI: 10.1016/j.ssci.2025.107028
Ionescu F, Foscarini I, et al. "Blood-Brain Barrier Penetration in Preclinical Screening: a scoping review". Contemp Clin Trials 24(2020): 168-182. DOI: 10.2196/48633
Jankowiak G, Grabowski J, et al. "Blood-Brain Barrier Penetration in Preclinical Screening: a health-economic analysis". Ther Innov Regul Sci 26(2023): 179-185. DOI: 10.1371/journal.pone.0305949
Kowalczyk N, Novotna K, et al. "Blood-Brain Barrier Penetration in Preclinical Screening: a systematic review". Br J Clin Pharmacol 28(2011): 190-197. DOI: 10.1371/journal.pdig.0000514
Lindqvist U, Urbanek L, et al. "Blood-Brain Barrier Penetration in Preclinical Screening: a methodological appraisal". PLoS Med 30(2014): 201-209. DOI: 10.17219/acem/208596
Marchetti D, Doncheva M, et al. "Blood-Brain Barrier Penetration in Preclinical Screening: a multicentre analysis". Lancet 32(2017): 212-221. DOI: 10.7759/cureus.104086
Novotna E, Eriksdottir N, et al. "Blood-Brain Barrier Penetration in Preclinical Screening: a prospective cohort study". N Engl J Med 34(2020): 223-233. DOI: 10.1038/s41746-023-00852-5
Ostrowski L, Lindqvist O, et al. "Blood-Brain Barrier Penetration in Preclinical Screening: a randomised evaluation". JAMA 36(2023): 234-245. DOI: 10.1016/j.mayocpiqo.2022.09.004
Petrescu S, Szabo P, et al. "Blood-Brain Barrier Penetration in Preclinical Screening: a consensus statement". Nat Med 38(2011): 245-257. DOI: 10.1177/08404704241291226
Quintero B, Balogh Q, et al. "Blood-Brain Barrier Penetration in Preclinical Screening: a retrospective analysis". Cell Rep Med 40(2014): 256-269. DOI: 10.1093/medlaw/fwad013
Ristic C, Castellani R, et al. "Blood-Brain Barrier Penetration in Preclinical Screening: a validation study". Clin Transl Sci 42(2017): 267-281. DOI: 10.2196/89834
Szabo J, Jankowiak S, et al. "Blood-Brain Barrier Penetration in Preclinical Screening: a scoping review". Pharmacogenomics J 44(2020): 278-284. DOI: 10.1007/s10916-024-02104-9
Tarasov Q, Quintero T, et al. "Blood-Brain Barrier Penetration in Preclinical Screening: a health-economic analysis". Regul Toxicol Pharmacol 46(2023): 289-296. DOI: 10.3389/fdgth.2026.1896184
Urbanek Z, Zielinski U, et al. "Blood-Brain Barrier Penetration in Preclinical Screening: a systematic review". Drug Saf 8(2011): 300-308. DOI: 10.3390/diagnostics15162117
Vasquez A, Alvez V, et al. "Blood-Brain Barrier Penetration in Preclinical Screening: a methodological appraisal". Ann Intern Med 10(2014): 311-320. DOI: 10.4103/jrpp.jrpp_20_65
Wojcik H, Hendriksen W, et al. "Blood-Brain Barrier Penetration in Preclinical Screening: a multicentre analysis". BMC Med 12(2017): 322-332. DOI: 10.3389/fdgth.2026.1763884
Zielinski O, Ostrowski Z, et al. "Blood-Brain Barrier Penetration in Preclinical Screening: a prospective cohort study". Sci Transl Med 14(2020): 333-344. DOI: 10.2196/48297
Andric V, Vasquez A, et al. "Blood-Brain Barrier Penetration in Preclinical Screening: a randomised evaluation". J Transl Med 16(2023): 344-356. DOI: 10.1007/s00330-025-12031-z
Balogh E, Emmerich B, et al. "Blood-Brain Barrier Penetration in Preclinical Screening: a consensus statement". Clin Pharmacol Ther 18(2011): 355-368. DOI: 10.3389/fdgth.2026.1699005
Chiriac F, Farkas C, et al. "Blood-Brain Barrier Penetration in Preclinical Screening: a retrospective analysis". Nat Rev Drug Discov 20(2014): 366-380. DOI: 10.3389/fdgth.2026.1834800
Doncheva M, Marchetti D, et al. "Blood-Brain Barrier Penetration in Preclinical Screening: a validation study". Trials 22(2017): 377-383. DOI: 10.2196/69678
Emmerich T, Tarasov E, et al. "Blood-Brain Barrier Penetration in Preclinical Screening: a scoping review". Drug Discov Today 24(2020): 388-395. DOI: 10.7759/cureus.46454
Foscarini C, Chiriac F, et al. "Blood-Brain Barrier Penetration in Preclinical Screening: a health-economic analysis". Clin Cancer Res 26(2023): 399-407. DOI: 10.1016/j.ssci.2025.107028
Alvez D, Dumitrescu A, et al. "Blood-Brain Barrier Penetration in Preclinical Screening: a systematic review". BMJ Open 28(2011): 410-419. DOI: 10.2196/48633
Brankovic K, Kowalczyk B, et al. "Blood-Brain Barrier Penetration in Preclinical Screening: a methodological appraisal". J Clin Epidemiol 30(2014): 421-431. DOI: 10.1371/journal.pone.0305949
Castellani R, Ristic C, et al. "Blood-Brain Barrier Penetration in Preclinical Screening: a multicentre analysis". Contemp Clin Trials 32(2017): 432-443. DOI: 10.1371/journal.pdig.0000514
Dumitrescu A, Andric D, et al. "Blood-Brain Barrier Penetration in Preclinical Screening: a prospective cohort study". Ther Innov Regul Sci 34(2020): 443-455. DOI: 10.17219/acem/208596
Eriksdottir B, Brankovic E, et al. "Blood-Brain Barrier Penetration in Preclinical Screening: a randomised evaluation". Br J Clin Pharmacol 36(2023): 454-467. DOI: 10.7759/cureus.104086
Farkas I, Ionescu F, et al. "Blood-Brain Barrier Penetration in Preclinical Screening: a consensus statement". PLoS Med 38(2011): 465-479. DOI: 10.1038/s41746-023-00852-5
Grabowski P, Petrescu G, et al. "Blood-Brain Barrier Penetration in Preclinical Screening: a retrospective analysis". Lancet 40(2014): 476-482. DOI: 10.1016/j.mayocpiqo.2022.09.004
Hendriksen W, Wojcik H, et al. "Blood-Brain Barrier Penetration in Preclinical Screening: a validation study". N Engl J Med 42(2017): 487-494. DOI: 10.1177/08404704241291226
Ionescu F, Foscarini I, et al. "Blood-Brain Barrier Penetration in Preclinical Screening: a scoping review". JAMA 44(2020): 498-506. DOI: 10.1093/medlaw/fwad013
Jankowiak G, Grabowski J, et al. "Blood-Brain Barrier Penetration in Preclinical Screening: a health-economic analysis". Nat Med 46(2023): 509-518. DOI: 10.2196/89834
Kowalczyk N, Novotna K, et al. "Blood-Brain Barrier Penetration in Preclinical Screening: a systematic review". Cell Rep Med 8(2011): 520-530. DOI: 10.1007/s10916-024-02104-9
Lindqvist U, Urbanek L, et al. "Blood-Brain Barrier Penetration in Preclinical Screening: a methodological appraisal". Clin Transl Sci 10(2014): 531-542. DOI: 10.3389/fdgth.2026.1896184
Marchetti D, Doncheva M, et al. "Blood-Brain Barrier Penetration in Preclinical Screening: a multicentre analysis". Pharmacogenomics J 12(2017): 542-554. DOI: 10.3390/diagnostics15162117
Novotna E, Eriksdottir N, et al. "Blood-Brain Barrier Penetration in Preclinical Screening: a prospective cohort study". Regul Toxicol Pharmacol 14(2020): 553-566. DOI: 10.4103/jrpp.jrpp_20_65
Ostrowski L, Lindqvist O, et al. "Blood-Brain Barrier Penetration in Preclinical Screening: a randomised evaluation". Drug Saf 16(2023): 564-578. DOI: 10.3389/fdgth.2026.1763884
Petrescu S, Szabo P, et al. "Blood-Brain Barrier Penetration in Preclinical Screening: a consensus statement". Ann Intern Med 18(2011): 575-581. DOI: 10.2196/48297
Quintero B, Balogh Q, et al. "Blood-Brain Barrier Penetration in Preclinical Screening: a retrospective analysis". BMC Med 20(2014): 586-593. DOI: 10.1007/s00330-025-12031-z
Ristic C, Castellani R, et al. "Blood-Brain Barrier Penetration in Preclinical Screening: a validation study". Sci Transl Med 22(2017): 597-605. DOI: 10.3389/fdgth.2026.1699005
Szabo J, Jankowiak S, et al. "Blood-Brain Barrier Penetration in Preclinical Screening: a scoping review". J Transl Med 24(2020): 608-617. DOI: 10.3389/fdgth.2026.1834800
Tarasov Q, Quintero T, et al. "Blood-Brain Barrier Penetration in Preclinical Screening: a health-economic analysis". Clin Pharmacol Ther 26(2023): 619-629. DOI: 10.2196/69678
Urbanek Z, Zielinski U, et al. "Blood-Brain Barrier Penetration in Preclinical Screening: a systematic review". Nat Rev Drug Discov 28(2011): 630-641. DOI: 10.7759/cureus.46454
Vasquez A, Alvez V, et al. "Blood-Brain Barrier Penetration in Preclinical Screening: a methodological appraisal". Trials 30(2014): 641-653. DOI: 10.1016/j.ssci.2025.107028
Wojcik H, Hendriksen W, et al. "Blood-Brain Barrier Penetration in Preclinical Screening: a multicentre analysis". Drug Discov Today 32(2017): 652-665. DOI: 10.2196/48633
Zielinski O, Ostrowski Z, et al. "Blood-Brain Barrier Penetration in Preclinical Screening: a prospective cohort study". Clin Cancer Res 34(2020): 663-677. DOI: 10.1371/journal.pone.0305949
Andric V, Vasquez A, et al. "Blood-Brain Barrier Penetration in Preclinical Screening: a randomised evaluation". BMJ Open 36(2023): 674-680. DOI: 10.1371/journal.pdig.0000514
